Overall, 58.3% of participants treated with tofacitinib 10mg twice daily responded by day 7, and in some cases improvement of clinical and biochemical parameters, including diarrhea, hematochezia, and CRP was observed as early as 2 days after tofacitinib initiation. The gene discussed is CRP; the disease is Hematochezia.